Hepatocarcinogenesis Driven by GSNOR Deficiency Is Prevented by iNOS Inhibition

Chi-Hui Tang1, Wei Wei1, Martha A. Hanes2, and Limin Liu1

Abstract

Hepatocellular carcinoma (HCC) is one of the most common and deadly human cancers and it remains poorly managed. Human HCC development is often associated both with elevated expression of inducible nitric oxide synthase (iNOS) and with genetic deletion of the major denitrosylase S-nitrosoglutathione reductase (GSNOR/ADH5). However, their causal involvement in human HCC is not established. In mice, GSNOR deficiency causes S-nitrosylation and depletion of the DNA repair protein O6-alkylguanine-DNA-alkyltransferase (AGT) and increases rates of both spontaneous and DEN carcinogen-induced HCC. Here, we report that administration of 1400W, a potent and highly selective inhibitor of iNOS, blocked AGT depletion and rescued the repair of mutagenic O6-ethyldeoxyguanosines following DEN challenge in livers of GSNOR-deficient (GSNOR−/−) mice. Notably, short-term iNOS inhibition following DEN treatment had little effect on carcinogenesis in wild-type mice, but was sufficient to reduce HCC multiplicity, maximal size, and burden in GSNOR−/− mice to levels comparable with wild-type controls. Furthermore, increased HCC susceptibility in GSNOR−/− mice was not associated with an increase in interleukin 6, tumor necrosis factor-α, oxidative stress, or hepatocellular proliferation. These results suggested that GSNOR deficiency linked to defective DNA damage repair likely acts at the tumor initiation stage to promote HCC carcinogenesis. Together, our findings provide the first proof of principle that HCC development in the context of uncontrolled nitrosative stress can be blocked by pharmacologic inhibition of iNOS, possibly providing an effective therapy for patients with HCC. Cancer Res; 73(9); 2897–904. ©2013 AACR.

Introduction

Hepatocellular carcinoma (HCC) is one of the most lethal human cancers and is the third leading cause of cancer deaths worldwide (1). The major risk factors for HCC are chronic hepatitis and cirrhosis caused by hepatitis B and C virus infection and heavy alcohol consumption, which affect hundreds of millions of people (2). Because of the spread of hepatitis C virus infection, HCC incidence and mortality in many parts of the world including the United States are rapidly increasing (2). The molecular mechanisms through which risk factors contribute to hepatocarcinogenesis remain poorly understood (3), resulting in a paucity of effective therapeutic approaches and extremely poor prognosis for patients with HCC.

The development of human HCC is often associated with elevated production of nitric oxide (NO) and an increase in nitrosative stress. Inducible nitric oxide synthase (iNOS), the enzyme responsible for the high production of NO in the innate immune response and inflammation, is often substantially increased at both mRNA and protein levels in hepatocytes of patients with chronic hepatitis B and C virus infection (4–6), hemochromatosis (7), and alcoholic cirrhosis (8), all of which are established risk factors of HCC (2). Furthermore, iNOS is expressed at high levels in hepatocytes within HCC (6, 9), and patients with HCC exhibit elevated concentrations of plasma nitrite/nitrate, the stable end products of NOS activity (10, 11). Expression of iNOS has also been described in the development of fibrosis-associated (12) or DEN-induced (13, 14) HCC in animal models. NO affects the functions of a wide range of proteins through S-nitrosylation, the covalent modification of cysteine thiols (15). Protein S-nitrosylation is increased by NO activity but downregulated by S-nitrosoglutathione reductase (GSNOR), a ubiquitous and highly conserved denitrosylase (16–18). By preventing excessive protein S-nitrosylation, GSNOR plays an evolutionarily conserved, critical role in protecting against nitrosative stress (16, 17). The human GSNOR gene (ADH5) is located at approximately 4q23, a region in which chromosomal deletion occurs frequently in cirrhotic and dysplastic hepatocytes and in HCC (19–23). Furthermore, the abundance and activity of GSNOR are significantly decreased in cancer samples from approximately 50% of patients with HCC (24).

Authors’ Affiliations: 1Department of Microbiology and Immunology, University of California, San Francisco, California; and 2Department of Laboratory Animal Resources, University of Texas Health Science Center, San Antonio, Texas

Note: Supplementary data for this article are available at Cancer Research Online (http://cancerres.aacrjournals.org/).

Corresponding Author: Limin Liu, Department of Microbiology and Immunology, University of California, 513 Parnassus Avenue, HSE-201J, San Francisco, CA 94143. Phone: 415-476-1466; Fax: 415-502-4995; E-mail: Limin.Liu@ucsf.edu

doi: 10.1158/0008-5472.CAN-12-3980

2013 American Association for Cancer Research.
has shown that both GSNOR deficiency and iNOS overexpression in the liver are closely associated with de novo hepatocarcinogenesis after tumor resection and a poor prognosis in patients with HCC (25). Despite the accumulating evidence suggesting that excessive S-nitrosylation and nitrosative stress from concurrent GSNOR deficiency and iNOS overexpression in the liver may contribute critically to human HCC, their precise involvement in the etiology of HCC has not been well studied and remains poorly defined.

Our previous studies using a mouse line with targeted deletion of the GSNOR gene suggested that S-nitrosylation from GSNOR deficiency promotes both spontaneous and DEN-induced HCC, thereby establishing a model for studying the important roles of dysregulated protein S-nitrosylation in hepatocarcinogenesis (24). In this model, we have shown that during inflammatory responses following intraperitoneal injection of DEN or lipopolysaccharide (LPS), GSNOR deficiency led to S-nitrosylation, ubiquitination, and proteasomal degradation of O6-alkylguanine-DNA-alkyltransferase (AGT). AGT is the major DNA repair enzyme responsible for repair of highly mutagenic and cytotoxic O6-alkylguanines (26) and is important for protecting against dialkylnitrosamine-induced HCC (27, 28). AGT, not susceptible to inactivation by tyrosine nitration, is highly susceptible to inactivation by S-nitrosylation (29). We have shown that in the livers of DEN-challenged GSNOR−/− mice, the repair of carcinogenic O6-ethyldeoxyguanosine was impaired, leading to their persistent elevation. Predisposition to HCC, S-nitrosylation and depletion of AGT, and accumulation of O6-ethyldeoxyguanosine due to GSNOR deficiency were all largely abrogated by concurrent deletion of the iNOS gene in GSNOR−/−iNOS−/− mice, suggesting an important role for iNOS-derived S-nitrosylation in AGT inactivation and liver carcinogenesis in GSNOR−/− mice (24). Moreover, hepatocyte-specific deletion of GSNOR caused nitrosative inactivation of liver AGT and increased DNA damage and mortality after DEN challenge (30), suggesting the importance of GSNOR regulation of S-nitrosylation in liver parenchymal cells. However, GSNOR, previously known as alcohol dehydrogenase class III, has been shown in vitro to have enzymatic activity toward long-chain primary alcohols as well as glutathione-dependent formaldehyde dehydrogenase activity (16, 31). In addition, findings derived by comparison of GSNOR−/− and GSNOR−/−iNOS−/− mice could be confounded by potential differences in genetic background or animal development between the 2 mouse lines. Thus, it is possible that dysregulated S-nitrosylation may not be the only mechanism through which GSNOR deficiency contributes to hepatocarcinogenesis. Furthermore, it is currently unclear during which stage of tumorigenesis, initiation or promotion, GSNOR deficiency has the critical effect on HCC development.

In the present study, we sought to determine whether increased hepatocarcinogenesis from GSNOR deficiency could be reduced by pharmacologic inhibition of NO production, which may represent a novel therapeutic approach to human HCC. As such, we used the highly selective pharmacologic inhibitor of iNOS, 1400W (32), to temporarily block iNOS activity during tumor initiation in the DEN-induced HCC model. We found that short-term iNOS inhibition after DEN-challenge reduces the acute genotoxic effects of DEN and significantly decreases the subsequent development of HCC.

Materials and Methods

Animals

GSNOR−/− mice (17) are in a C57BL/6 background after 10 consecutive backcrosses with the wild-type mice. Both GSNOR−/− and C57BL/6 mice were kept in ventilated filter-top cages with centralized water supplies and maintained on normal mouse chow (5058 PicoLab Mouse Diet 20) in a specific pathogen-free facility at the University of California at San Francisco (UCSF). The experimental protocol was approved by the Institutional Animal Care and Use Committee of UCSF.

Acute DEN treatment and iNOS inhibition

Male GSNOR−/− and wild-type C57BL/6 mice were given at postnatal day 15 a single intraperitoneal injection of DEN (50 μg/g body weight). For 4 days after DEN treatment, the DEN-challenged mice were given intraperitoneal injections of phosphate-buffered saline (PBS) or 1400W (1 μg/g) twice daily to inhibit iNOS activity as we did previously (17). The inhibitor was not given in oral because of its poor oral bioavailability (33). On day 5, the mice were euthanized and liver samples were collected. Levels of alanine aminotransferase (ALT) were analyzed by University of California Davis Comparative Pathology Laboratory.

Chemical hepatocarcinogenesis

Male GSNOR−/− and wild-type C57BL/6 mice, 3 to 5 per group, were given at postnatal day 15 a single intraperitoneal injection of DEN (5 μg/g) dissolved in PBS. Starting at 6 hours after DEN challenge, half of the mice in a cage were intraperitoneally injected with 1400W (1 μg/g) once daily for 4 days, whereas the other half of the mice were injected with PBS. Mice are weaned at postnatal day 21 to 22 and kept under standard barrier conditions. Mice were sacrificed 9 months after DEN challenge, and livers were harvested and examined for tumor growth. Visible superficial tumors were counted and measured. Tumor burden was estimated by the sum of the calculated areas (πr²) of counted tumors.

Immunoblot

Liver lysates were prepared by homogenization of samples on ice in a lysis buffer containing 50 mmol/L Tris-HCl, pH 8.0, 0.1% NP-40, 1 mmol/L EDTA, 0.1 mmol/L DTPA, 150 mmol/L NaCl, 1 mmol/L phenylmethylsulfonyl fluoride, and a protease inhibitor cocktail (Roche). Proteins (25–50 μg) were separated by SDS-PAGE under reducing conditions, transferred to nitrocellulose membranes, and probed with a goat antiserum against AGT (R&D Systems), or a monoclonal antibody against β-actin (A5441; Sigma) followed by detection with corresponding secondary antibodies coupled to Alexa Fluor 680 (Invitrogen) or IRDye 800 (Rockland Immunochemicals), and imaged and quantified using an infrared fluorescence imaging system (Odyssey; LICOR Biosciences; ref. 30). The fluorescent signal corresponding to AGT, normalized to that of β-actin, was compared with the mean of the control in each experiment.
A rabbit polyclonal antibody (kindly provided by Dr. Harry Ischiropoulos) was used for the detection of nitrotyrosine.

**Immunostain–blot**

O6-ethyldeoxyguanosine (O6-etdG) and O2-ethyldeoxythymidine (O2-etdT) lesions were detected as previously described (24). Briefly, genomic DNA was isolated from the livers of mice injected with DEN (50 μg/g intraperitoneally, at postnatal day 15) and 0 or 1 μg/g of 1400W (for 4 days). Ethynylthiosemicarbazone-treated call thymus DNA was used as a positive control. The DNA was sonicated, denatured, and transferred to nitrocellulose membrane using a Bio-Dot slot blotting apparatus (Bio-Rad). Lesions were detected using a rat monoclonal antibody against O6-etdG (ER6, Axxora) or a mouse monoclonal antibody against O2-etdT (EM 4-I, Axxora) and imaged using Femto Chemiluminescent Substrate (Thermo Scientific) on Hyperfilm ECL film (GE Healthcare). The optical density of the scanned image was quantified using Odyssey Application Software. The signal corresponding to O6-etdG in a 1400W-treated sample was compared with the mean of the PBS-treated control in each experiment.

**Glutathione, glutathione disulfide, and glutathione reductase activity**

Glutathione (GSH) levels are determined by a glutathione disulfide (GSSG) reductase recycling assay modified from Griffith (34). Liver samples are homogenized by sonication in 5 volumes per gram of wet tissue weight of 5% sulfosalicylic acid. The liver homogenates are centrifuged, and the supernatants are measured immediately for total glutathione (GSH + GSSG). To determine glutathione disulfide, and glutathione levels are normalized with protein contents in the liver homogenates. Glutathione reductase activity was measured essentially as described by Smith et al. (35).

**8-hydroxy-2'-deoxyguanosine (8-OHdG) measurement**

Genomic DNA from the livers of DEN-treated mice was purified (GenElute Mammalian Genomic DNA kit) in the presence of 0.1 mmol/L desferal, an iron chelator to prevent autooxidation of DNA in vitro. Single-strand DNA was generated with boiling followed by rapid cooling on ice. After addition of sodium acetate (pH 5.3, 100 mmol/L final), DNA was digested with 1U nuclease P1 at 50°C for 2 hours. The pH was adjusted with 1mol/L Tris-HCl (pH 8.0) and the DNA was treated with alkaline phosphatase at 37°C for 1 hour. The digest was centrifuged for 5 minutes at 10,000 × g. The supernatant containing nucleotides was assayed for 8-OHdG using an EIA kit (Catalog number 589320, Cayman Chemical) according to manufacturer protocol. Absorbance at 410 nm in the absence (B0) or presence (B) of DNA, through the logit transformation, ln[(B/B0)/(1 – B/B0)], was used to generate the standard curve and to calculate the concentration of 8-OHdG in the samples.

**Real-time quantitative PCR**

RNA from the livers of DEN-treated mice was isolated by Trizol/Chloroform extraction followed by silica-cartridge purification (PureLink RNA Mini Kit, Ambion). RNA quantity and quality were determined by UV absorbance at 260 nm and A260/280 ratio, respectively, using a NanoDrop spectrophotometer. Quantitative RT-PCR was conducted using the Power SYBR Green RNA-to-Ct 1-Step Kit (Applied Biosystems) according to manufacturer’s protocol. Primers used are as follows: interleukin 6 (IL-6): 5′-TGTGTCCTTCTCACTACCCCAATTTC-3′ and 5′-TTTGTTCTTACGACCTCTCTTC3′ (PrimerBank ID 1362431A1); tumor necrosis factor-α (TNF-α): 5′-CCCTCACACTCAGATCATCTTCT-3′ and 5′-GCTACGACGTTGGCTACAG-3′ (PrimerBank ID 7305585A1); and glyceraldehyde-3-phosphate dehydrogenase (GAPDH): 5′-AATGTTGAAGGTCGTTGTG-3′ and 5′-GGGCTACAGTGTTAG-3′ (PrimeTime Mm.PT.39a1, IDT). The specificity of PCR product was determined by melt curve and agarose gel analyses.

**Cytokines**

Liver IL-6 and TNF-α expression was quantified using the Luminex Cytokine assay (Invitrogen) per manufacturer’s protocol.

**Statistical analysis**

Tumor number, maximal size, and burden of each group were compared using a 2-tailed, unpaired Student t test. Comparison of the results using the Mann–Whitney U test yielded similar results. Other data were analyzed with a 2-tailed, unpaired Student t test.

**Results**

**Pharmacologic inhibitor of iNOS prevents AGT depletion in DEN-challenged GSNOR−/− mice**

We employed the DEN model to determine whether acute nitrosative inactivation of AGT in GSNOR−/− mice can be prevented by pharmacologic inhibition of iNOS. While AGT decrease after nitrosamine treatment largely recovers by day 4 in wild-type mice (36), AGT level remains low in GSNOR−/− mice. These data provide pharmacologic evidence that AGT is highly susceptible to nitrosative inactivation.

**Inhibition of iNOS after DEN challenge reduces O6-ethyldeoxyguanosine lesions in the liver of GSNOR−/− mice**

To address whether the protection of AGT by iNOS inhibition rescues the repair of O6-alkylguanines in the DEN-challenged GSNOR−/− mice, liver genomic DNA was analyzed for the presence of O6-alkylguanines by immunostain–blot using a monoclonal antibody against O6-etdG (Fig. 2). We detected substantial amounts of O6-etdG after DEN treatment, and the levels of O6-etdG were decreased approximately 5-fold by 1400W treatment (Fig. 2). Levels of O2-etdT, a DEN-induced...
Figure 1. Inhibition of iNOS by 1400W reverses AGT depletion after DEN treatment. A postnatal day 15 GSNOR−/− mice were injected intraperitoneally with DEN. Starting at 6 hours after DEN injection, 1400W (+) or PBS (−) was administered intraperitoneally twice daily for 4 days. Livers were collected on day 5, and lysates were analyzed by immunoblot using antibodies against AGT and β-actin. Each lane represents an individual mouse. B, quantification of AGT protein detected by immunoblot. AGT levels (mean ± SE) in 1400W-treated mice (n = 4) were significantly higher than that in control mice (n = 4; P = 0.004, 2-tailed Student t test).

Figure 2. Inhibition of iNOS by 1400W reduces DEN-induced O6-ethyldeoxyguanosine (O6-etdG) lesions. A, genomic DNA was isolated from liver samples described in Fig. 1. The DNA (1 µg per lane) was analyzed by immuno blot using monoclonal antibodies against O6-etdG and O6-ethyldeoxyguanosine (O6-etdG; top). Ethylnitrosourea-alkylated calf thymus DNA (40, 20, 10, and 5 ng) was used as a positive control (bottom). B, quantification of relative O6-etdG levels. O6-etdG levels (mean ± SE) in 1400W-treated mice (n = 3) were significantly lower than in control mice (n = 3; P = 0.013, 2-tailed Student t test).

Short-term 1400W treatment during tumor initiation reduces DEN-induced tumorigenesis in GSNOR−/− mice

Since we have shown that short-term inhibition of iNOS by 1400W was capable of protecting AGT and preventing accumulation of O6-alkylguanines, we used the DEN-induced HCC model according to the scheme in Fig. 3A to determine whether short-term inhibition of iNOS for 4 days will reduce long-term tumorigenesis. As shown in Fig. 3B, we found that DEN-challenged GSNOR−/− mice typically developed numerous large liver tumors after 9 months. However, fewer and smaller tumors developed in GSNOR−/− mice treated with 1400W (Fig. 3B). Histopathologic analysis has shown, in 1400W-treated and control mice, the development of both hepatocellular adenomas and carcinomas (Fig. 3C).

We quantitatively evaluated the effect of iNOS inhibition on DEN-induced liver tumorigenesis in both wild-type and GSNOR−/− mice (Fig. 4). Consistent with previous reports (24), DEN challenge in the absence of iNOS inhibition resulted in significantly higher tumor numbers in GSNOR−/− mice (n = 15) than in wild-type mice (n = 15; P = 4.4 x 10−6, Fig. 4A). Importantly, while almost all DEN-treated GSNOR−/− mice developed liver tumors, short-term 1400W treatment following DEN challenge (n = 17) resulted in a 70% reduction of tumor numbers in GSNOR−/− mice (P = 8.1 x 10−6, Fig. 4A). Similar 1400W treatment in DEN-challenged wild-type mice (n = 13) had no effect on tumor multiplicity. Interestingly, 1400W treatment of GSNOR−/− mice brings the tumor number down to the level of wild-type mice. Thus, these data strongly suggest that tumor multiplicity in DEN-challenged GSNOR−/− mice critically depends on nitrosative stress in the initiation phase of tumorigenesis.

We next analyzed tumor size in the 4 experimental groups (Fig. 4B). Consistent with previous reports (24), DEN challenge resulted in significant increase in maximal tumor size in GSNOR−/− versus wild-type mice (Fig. 4B, P = 0.0085). Short-term 1400W treatment following DEN challenge had no effect on maximal tumor size in wild-type mice (Fig. 4B), and 1400W did not affect HCC cell growth in culture (Supplementary Fig. S1). However, short-term 1400W treatment resulted in a significant reduction of maximal tumor size in GSNOR−/− mice (Fig. 4B, P = 0.0058). Indeed, 1400W treatment of GSNOR−/− mice brings the maximal tumor size down to the level of wild-type mice. Thus inhibition of nitrosative stress during tumor initiation in DEN-challenged GSNOR−/− mice reduced maximal tumor size.

For the 4 experimental groups, we also analyzed tumor burden, which was calculated as the sum of the tumor area for each animal (Fig. 4C). DEN challenge led to an over 3-fold increase in tumor burden in GSNOR−/− mice when compared with wild-type control (P = 0.00042). Again, short-term 1400W treatment following DEN challenge had no effect on wild-type mice but significantly reduced tumor burden in GSNOR−/− mice, decreasing it to the level of wild-type mice. Thus inhibition of nitrosative stress during tumor initiation in GSNOR−/− mice also reduced tumor burden.

Liver injury, inflammation, and proliferation following DEN treatment are comparable in wild-type and GSNOR−/− mice

DEN can cause liver damage and inflammation, resulting in compensatory proliferation, which may contribute to DEN-induced HCC (37). We found that serum ALT levels, a measure of liver injury, are comparable between DEN-challenged GSNOR−/− mice and wild-type controls (Fig. 5A). Since
inflammatory IL-6 and TNF-α were previously shown to promote HCC (37, 38), we analyzed livers from DEN-treated mice by quantitative PCR for the expression levels of IL-6 and TNF-α mRNA (Fig. 5B). The expression levels of IL-6 and TNF-α in DEN-challenged GSNOR−/− and wild-type mice did not differ significantly (Fig. 5B). Similarly, IL-6 and TNF-α protein levels in the liver were not significantly different between DEN-challenged wild-type and GSNOR−/− mice either (Fig. 5C). Thus, GSNOR deficiency does not seem to directly affect IL-6 and TNF-α expression after DEN challenge. To assess whether proliferation differed between DEN-treated wild-type and GSNOR−/− mice, we conducted immunohistochemical analysis of Ki-67, a marker of proliferating cells. Again, we found no significant difference in proliferation in DEN-challenged wild-type and GSNOR−/− mice (Fig. 5D). Thus, these parameters do not seem to contribute significantly to the increase in HCC promoted by GSNOR deficiency.

DEN treatment may cause acute oxidative stress (39); persistent oxidative damage from deficiency in the antioxidant enzyme CuZn-superoxide dismutase can lead to increased incidence of HCC (40). We found that the levels of glutathione, glutathione disulfide, and glutathione reductase activity in the livers of GSNOR−/− mice did not differ significantly from that in wild-type control (Supplementary Fig. S2). Neither DEN alone nor DEN with 1400W affected glutathione reductase activity (Supplementary Fig. S2B). Moreover, the levels of 8-OHdG, a major DNA product from oxidative stress, are comparable in the livers of DEN-treated GSNOR−/− and wild-type mice (Supplementary Fig. S3). We also analyzed protein tyrosine nitration in the livers of DEN-treated mice by immunoblot and found no increase in overall protein tyrosine nitration by GSNOR deficiency (Supplementary Fig. S4). Thus, the livers of GSNOR−/− mice, compared with wild-type controls, do not seem to suffer significantly increased oxidative stress.

**Discussion**

We previously showed that GSNOR deficiency resulted in an iNOS-dependent increase in susceptibility to spontaneous and DEN-induced HCC (24). In the present study, we investigated whether during the stage of tumor initiation, S-nitrosylation and nitrosative stress from GSNOR deficiency has the critical effect on HCC development. We have shown that pharmacologic inhibition of iNOS activity during DEN challenge in GSNOR−/− mice prevented both the depletion of the important DNA repair protein AGT and persistent elevation of carcinogenic O6-alkylguanines. Importantly, we have shown that short-term iNOS inhibition during the stage of tumor initiation by DEN was sufficient to reduce HCC multiplicity, maximal
size, and burden in GSNOR−/− mice to levels observed in wild-type mice. Furthermore, we found that increased HCC susceptibility in GSNOR−/− mice was not associated with an increase in IL-6, TNF-α, oxidative stress, or hepatocellular proliferation. Thus, the results suggest that S-nitrosylation from GSNOR deficiency, likely through the inhibition of DNA damage repair, promotes hepatocarcinogenesis at the stage of tumor initiation. Our findings provide the first evidence that HCC development in the context of uncontrolled nitrosative stress can be inhibited by pharmacologic inhibitor of iNOS.

Employing a pharmacologic inhibitor specific to iNOS in DEN-challenged GSNOR−/− mice, we provided evidence for a critical role of nitrosative stress in HCC development at the stage of tumor initiation. Previously, we have shown that the increase in susceptibility to both spontaneous and DEN-induced HCC from GSNOR deficiency was abolished in GSNOR+/−iNOS−/− mice, providing genetic evidence for an important role of iNOS-derived S-nitrosylation in HCC development (24). Nevertheless, the GSNOR−/− and GSNOR+/−iNOS−/− mice are not expected to have exactly the same genetic background, and genetic deletion of iNOS might result in compensatory changes in the development of GSNOR−/−iNOS−/− mice. These genetic and possible developmental differences may compromise interpretation of the results obtained from the 2 mouse lines. Furthermore, the genetic approach is not amenable to dissecting the role of dysregulated S-nitrosylation in the various stages of tumor development. The issues inherently associated with comparison of 2 mouse lines were avoided in the present study, which was carried out in a single GSNOR−/− line. Our results with iNOS inhibition also addressed the concern raised by in vitro studies that GSNOR has dehydrogenase activities toward chemicals unrelated to S-nitrosylation. More importantly, the present work established a carcinogenic role for nitrosative stress specifically at tumor initiation. This is supported by the findings that the important DNA repair protein AGT is highly susceptible to S-nitrosylation-dependent inactivation (24, 29). We have recently shown that as the frequency of O6-methylguanine at G:C to T:A mutations was not elevated in DEN-challenged GSNOR−/− mice compared with wild-type control, the frequency of the transition from G:C to A:T, a mutation deriving from DEN-induced O6-methylguanines that are normally repaired by AGT, was significantly increased by GSNOR deficiency (41). Overall, our findings suggest that in the mouse model, S-nitrosylation-dependent AGT inactivation as a result of GSNOR deficiency is a major contributor to increased mutagenesis and hepatocarcinogenesis. As S-nitrosylation can affect functions of a wide range of proteins, including many important to tumorigenesis (42), it remains to be explored that dysregulated S-nitrosylation from GSNOR deficiency may promote HCC by altering activities or functions of additional proteins during tumor initiation or other stages of hepatocarcinogenesis.

We found that inhibition of iNOS activity by 1400 W did not affect HCC multiplicity, maximal size, or burden in DEN-challenged wild-type mice. Although cytotoxicity from NO or related activity, particularly at high levels provided from exogenous sources, has been shown for numerous cells including HCC cell lines (43), it is well established that NO produced endogenously by NO synthase (NOS) inhibits death of hepatocytes (44). Using INOS−/− mice in both spontaneous and fibrosis-associated models of HCC, Denda and colleagues showed that iNOS activity has neither promoting nor inhibitory effect on hepatocarcinogenesis (12). Consistent with these findings, our current study further showed that in the presence of wild-type GSNOR, iNOS activity has little effect on hepatocellular tumor initiation in the DEN model. Thus, the pro-hepatocarcinogenic activity of iNOS, shown both genetically (24) and pharmacologically, is normally prevented by GSNOR. These results suggest that potential therapeutic approaches utilizing iNOS inhibition in patients with HCC should take GSNOR status into consideration.
Our findings of a critical role for GSNOR deficiency during tumor initiation may have important implications for understanding the pathogenesis of human HCC. Substantially elevated expression of iNOS has been extensively described in hepatocytes in both HCC and many pathologic conditions predisposing to HCC (4–9). Somatic deletion of the human GSNOR gene (ADH5) occurs frequently in cirrhotic and dysplastic hepatocytes and in HCC (19–23), and significant reductions in the levels of both GSNOR protein and activity are apparently common in human HCC (24). Hoshida and colleagues have shown through mRNA-expression profiling that in nontumoral liver tissues adjacent to resected primary tumors in patients with HCC, an increase in iNOS expression and a decrease in GSNOR expression are both closely associated with de novo hepatocarcinogenesis after tumor resection and a poor prognosis (25). The underlying mechanism of the association of iNOS and GSNOR with human HCC remains unclear, but our previous results and present findings suggest that excessive S-nitrosylation from concurrent GSNOR deficiency and iNOS over-expression may cause nitrosative inactivation of DNA repair systems, providing a driving force for mutagenesis and hepatocarcinogenesis.

Preventing increased hepatocarcinogenesis from GSNOR deficiency by pharmacologic inhibitor of iNOS, shown here as a proof of principle in a mouse model, may provide the basis for a potential therapeutic approach to patients with HCC. In patients having concurrent GSNOR deficiency and iNOS over-expression in liver tissues adjacent to primary HCC, iNOS inhibition after tumor resection may be particularly attractive as an adjuvant therapeutic approach, which may provide a significant survival benefit. In addition, our findings suggest that loss of GSNOR in prneoplastic liver tissues could increase overall risk of HCC and therefore may have prognostic value. Inhibition of excessive S-nitrosylation in these patients may help to prevent HCC development.

Disclosure of Potential Conflicts of Interest
No potential conflicts of interest were disclosed.

Authors’ Contributions
Conception and design: C.H. Tang, W. Wei, L. Liu
Development of methodology: C.H. Tang, W. Wei, L. Liu
Acquisition of data (provided animals, acquired and managed patients, provided facilities, etc.): C.H. Tang, W. Wei, L. Liu
Analysis and interpretation of data (e.g., statistical analysis, biostatistics, computational analysis): C.H. Tang, L. Liu
Writing, review, and/or revision of the manuscript: C.H. Tang, L. Liu
Administrative, technical, or material support (i.e., reporting or organizing data, constructing databases): C.H. Tang, W. Wei, L. Liu
Study supervision: L. Liu

Other: Reviewed histologic slides prepared from study experimental animals and interpreted histopathologic lesions, M.A. Hanes

Grant Support
This work was supported by the NIH (R01CA55578 and R01CA122359 to L.Liu; P30 DK026743 to UCSF Liver Center).

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1754 solely to indicate this fact.

Received October 18, 2012; revised February 13, 2013; accepted February 14, 2013; published OnlineFirst February 21, 2013.

References


Hepatocarcinogenesis Driven by GSNOR Deficiency Is Prevented by iNOS Inhibition

Chi-Hui Tang, Wei Wei, Martha A. Hanes, et al.


Updated version
Access the most recent version of this article at:
doi:10.1158/0008-5472.CAN-12-3980

Supplementary Material
Access the most recent supplemental material at:
http://cancerres.aacrjournals.org/content/suppl/2013/02/25/0008-5472.CAN-12-3980.DC1

Cited articles
This article cites 42 articles, 16 of which you can access for free at:
http://cancerres.aacrjournals.org/content/73/9/2897.full.html#ref-list-1

Citing articles
This article has been cited by 1 HighWire-hosted articles. Access the articles at:
/content/73/9/2897.full.html#related-urls

E-mail alerts
Sign up to receive free email-alerts related to this article or journal.

Reprints and Subscriptions
To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions
To request permission to re-use all or part of this article, contact the AACR Publications Department at permissions@aacr.org.